Biogen Sets Industry Record with Recognition on Dow Jones
Sustainability World Index for 9th Consecutive Year
Biogen Inc. (Nasdaq: BIIB) announced that it has set an industry
record as the most frequently recognized biotechnology company on
the Dow Jones Sustainability World Index (DJSI World), earning
recognition for the ninth consecutive year, more than any other
biotechnology company. The acknowledgment highlights the company’s
longstanding leadership actions and transparency on environmental,
social and governance (ESG) issues.
Biogen’s recognition on the DJSI World is a testament to the
company’s ongoing efforts to address the urgent and long-term
challenges facing humanity, including health equity; innovation;
the climate crisis; and human capital development with a focus on
diversity, equity and inclusion (DE&I). Notably, in 2021, the
company released its first public DE&I Report and supported a
number of bold, cross-sector climate commitments during the 26th UN
Climate Change Conference of the Parties (COP26), including the
U.K. NHS Net Zero initiative and the World Economic Forum’s new
Alliance for Clean Air.
“At Biogen, we have purposefully integrated corporate
responsibility into everything we do because we believe true
transformation requires collective, enduring efforts,” said Michel
Vounatsos, Chief Executive Officer of Biogen. “We are proud to be
recognized on the DJSI World for the ninth consecutive year, an
achievement that reflects our pioneering spirit and drive to
address the defining issues of our time, such as the interrelated
challenges of climate, health and equity. The public is depending
on us to act. As leaders, we must be willing to answer their
call.”
Every year, the DJSI World recognizes the top 10% of companies
in the S&P Global Broad Market Index for performance on ESG
issues, which S&P Global considers key to generating long-term
stakeholder value. This year saw more than 10,900 eligible
companies and a 33% year-over-year increase in participants
globally. The DJSI World ranking results from Biogen’s outstanding
performance on multiple dimensions of corporate responsibility,
including Innovation Management, Climate Strategy and Environmental
Reporting, where it received the top scores in industry. In 2013,
Biogen was the first U.S.-based biotechnology company to appear on
DJSI World.
"We congratulate Biogen for being included in the Dow Jones
Sustainability Index (DJSI) for DJSI World and DJSI North America,”
said Manjit Jus, Global Head of ESG Research, S&P Global. “A
DJSI distinction is a reflection of being a sustainability leader
in your industry. The record number of companies participating in
the 2021 S&P Global Corporate Sustainability Assessment is
testament to the growing movement for ESG disclosure and
transparency."
Reflecting progress on its ESG commitments, Biogen recently
celebrated the one-year anniversary of Healthy Climate, Healthy
Lives™, a $250 million, 20-year initiative to eliminate fossil
fuels across its operations and collaborate with renowned
institutions to address the health impacts of the climate crisis,
particularly for vulnerable populations. To recognize this
important milestone, the company released a one-year progress
report, which outlined efforts to enhance climate solutions
that promote public health, including sustaining
100% renewable electricity and directing 24% of
its spend to suppliers that have or pledged to
set science-based targets.
Details on Biogen’s ESG commitments can be found in
the 2020 Year In Review, which is based on internationally
recognized guidelines from the Global Reporting Initiative (GRI),
the Sustainability Accounting Standards Board (SASB), the UN SDGs
and the Stakeholder Capitalism Metrics published by the
International Business Council of the World Economic
Forum.
About BiogenAs pioneers in neuroscience, Biogen
discovers, develops, and delivers worldwide innovative therapies
for people living with serious neurological diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize
winners Walter Gilbert and Phillip Sharp. Today, Biogen has the
leading portfolio of medicines to treat multiple sclerosis, has
introduced the first approved treatment for spinal muscular
atrophy, and is providing the first and only approved treatment to
address a defining pathology of Alzheimer’s disease. Biogen is also
commercializing biosimilars and focusing on advancing the
industry’s most diversified pipeline in neuroscience that will
transform the standard of care for patients in several areas of
high unmet need.
In 2020, Biogen launched a bold 20-year, $250 million initiative
to address the deeply interrelated issues of climate, health, and
equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil
fuels across the company’s operations, build collaborations with
renowned institutions to advance the science to improve human
health outcomes, and support underserved communities.
The company routinely posts information that may be important to
investors on its website at www.biogen.com. To learn more,
please visit www.biogen.com and follow Biogen on social
media
– Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor This news release
contains forward-looking statements, including statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, about our strategy and plans;
anticipated benefits and potential of investments related to
Healthy Climate, Healthy Lives, our DE&I initiatives and other
related ESG and corporate responsibility initiatives; results that
may be achieved through our Healthy Climate, Healthy Lives
initiative, our DE&I initiatives and other related ESG and
corporate responsibility initiatives; the anticipated timeline of
our Healthy Climate, Healthy Lives initiative, our DE&I
initiatives and other related ESG and other corporate
responsibility initiatives; and capital allocation and investment
strategy. These statements may be identified by words such as
“aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,”
“forecast,” “goal,” “intend,” “may,” “plan,” “possible,”
“potential,” “will,” “would” and other words and terms of similar
meaning. You should not place undue reliance on these statements or
the scientific data presented.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including without limitation the risks of
unexpected hurdles, costs or delays; uncertainty of success in the
execution of our strategy and plans; risks that the goals of our
Healthy Climate, Healthy Lives, our DE&I initiatives and other
related ESG and corporate responsibility initiatives will be
completed in a timely manner or at all; uncertainty as to whether
the anticipated benefits of our Healthy Climate, Healthy Lives, our
DE&I initiatives and other related ESG and corporate
responsibility initiatives can be achieved; the direct and indirect
impacts of the ongoing COVID-19 pandemic on our business, results
of operations and financial condition; and the risks and
uncertainties that are described in the Risk Factors section of our
most recent annual or quarterly report and in other reports we have
filed with the U.S. Securities and Exchange Commission. The
foregoing sets forth many, but not all, of the factors that could
cause actual results to differ from our expectations in any
forward-looking statement. Investors should consider this
cautionary statement as well as the risk factors identified in our
most recent annual or quarterly report and in other reports we have
filed with the U.S. Securities and Exchange Commission. These
statements are based on our current beliefs and expectations and
speak only as of the date of this news release. We do not undertake
any obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or
otherwise.
MEDIA
CONTACT:BiogenAshleigh Koss+ 1 908 205
2572public.affairs@biogen.com |
INVESTOR
CONTACT:BiogenMike Hencke+1 781 464
2442IR@biogen.com |
Biogen (TG:IDP)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Biogen (TG:IDP)
Historical Stock Chart
Von Mär 2023 bis Mär 2024